Dupilumab: Eerste resultaten vanuit het BioDay-register

Translated title of the contribution: Dupilumab: Initial results from the BioDay registry

Lieneke F.M. Ariëns, J. van der Schaft, D. S. Bakker, D. M.W. Balak, B. Giovannone, M. Romeijn, T. Kouwenhoven, M. Kamsteeg, J. Drylewicz, F. van Wijk, S. Nierkens, J. L. Thijs, M. L. Schuttelaar, M. S. de Bruin-Weller

Research output: Contribution to journalArticlepeer-review


The effectiveness and safety of dupilumab for the treatment of moderate to severe atopic dermatitis (AD) has been demonstrated in phase III clinical trials. At this moment, daily practice data on dupilumab treatment with respect to clinical effectiveness and safety are scarce. The objective of this study was to study the clinical effectiveness of 16 weeks treatment with dupilumab in adult patients with moderate to severe AD in daily practice. Data were extracted from the BioDay registry, a prospective multicenter registry. Sixteen-weeks clinical effectiveness of dupilumab was expressed as number of patients achieving EASI-50, EASI-75 as well as patient reported outcome measures (POEM, DLQI, NRS-pruritus). A clinically relevant response was defined based on thresholds in one or more outcomes of the 3 major AD domains (EASI, NRS-pruritus, DLQI). In total, 138 patients treated with dupilumab in daily practice were included. This cohort included patients with very difficult- to-treat AD with 84 patients (61%) who failed treatment on ≥2 immunosuppressive drugs. At week 16, the mean percent change in EASI score was 73%. The EASI-50 and EASI-75 was achieved by 114 (86%) and 82 (62%) patients after 16 weeks of treatment. Also patient-reported outcomes including sleep, itch and quality of life significantly improved during dupilumab treatment. A clinically relevant response was achieved by 89% of the patients after 16 weeks of treatment. The most reported side effects were conjunctivitis in 47 (34%) and eosinophilia in 78 (57%) patients. In conclusion, treatment with dupilumab significantly improved signs and symptoms of AD in patients with very difficult-to-treat AD in a daily practice setting with the majority of patients achieving a clinically relevant response after 16 weeks of treatment.

Translated title of the contributionDupilumab: Initial results from the BioDay registry
Original languageDutch
Pages (from-to)29-34
Number of pages6
JournalNederlands Tijdschrift voor Dermatologie en Venereologie
Issue number4
Publication statusPublished - Apr 2019
Externally publishedYes


Dive into the research topics of 'Dupilumab: Initial results from the BioDay registry'. Together they form a unique fingerprint.

Cite this